

The specification has been amended to include the Sequence Listing submitted herewith on separate sheets. Entry of the Sequence Listing does not raise the issue of new matter as the sequence information contained therein is presented in the application as originally filed. The computer readable copy of the Sequence Listing submitted herewith is believed to be the same as the attached paper copy of that Listing.

The Notification of Defective Response indicates that Figures 1, 4 and 6 and pages 32, 33 and 35 contain nucleic acid sequences that were not set out in the prior filed Sequence Listing. In fact, there are no nucleic acid sequences referred to in the Figures, only polypeptide sequences. It is assumed, therefore, that reference to polypeptide sequences was intended. In addition, there are no sequences set out in Figure 4. There are, however, polypeptide sequences set out in Figure 5 which appears as sheet 4/6 of the drawings. It is assumed, therefore, that reference to Figure 5 (not to Figure 4) was intended. The Sequence Listing submitted herewith includes the sequences set out in Figures 1, 5 and 6 and at pages 32, 33, 35 and 36 that were not set out in the prior filed Sequence Listing.

The attached Sequence Listing is formatted as follows:

1. SEQ ID NOS:1 to 12 of the attached Sequence Listing correspond to SEQ ID NOS:1 to 12, respectively, of the Sequence Listing as published with the International Application from which the present case derives.

2. The rat DDAHI sequence set out in Figure 1 appears as new SEQ ID NO:14. The human DDAHI and II sequences set out in Figure 1 appear as SEQ ID NOS:2 and 4, respectively.

3. The three sequences set out in Figure 5 appear as new SEQ ID NOS:15 to 17, respectively.

4. The *S. coelicolor* DDAH, *P. aeruginosa* DDAH and human DDAHI sequences set out in Figure 6A correspond to SEQ ID NOS:6, 8 and 2, respectively. The *M. tuberculosis* DDAH sequence in Figure 6A is set out as new SEQ ID NO:13.


5. The *P. aeruginosa* deiminase and DDAH sequences set out in Figure 6B correspond to SEQ ID NOS:18 and 19, respectively.

6. The oligonucleotide sequences set out at page 32 are incorporated as new SEQ ID NOS:20 to 26; those at page 33 as new SEQ ID NOS:27 to 35; those at page 35 as new SEQ ID NOS:36 to 41 and those at page 36 as new SEQ ID NOS:42 and 43.

An early and favorable Action on the merits is
requested.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By 
Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100